Drug Policy Watch · State Brief 2026

Oklahoma

Snapshot (structured)

Adult-use cannabis: Illegal. Voters rejected SQ 820 in March 2023 (62 to 38 percent), and the 2026 legalization effort (SQ 837) was withdrawn in November 2025 after falling short on signatures.
Medical cannabis: Legal since 2018 (SQ 788). Unusually open, low-barrier market with no plant-count or product caps on patients and a famously cheap, fast licensing path, though a license moratorium has been in place since 2022.
Home grow: Allowed for medical patients only. SQ 788 permits patients to grow up to 6 mature plants and 6 seedlings. No adult-use home grow.
Intoxicating hemp / hemp THC: Sold widely. Delta-8 and similar converted cannabinoids remain legal at retail as of mid-2026; HB 3770 (2022) on paper restricts certain intoxicating-hemp sales to OMMA dispensaries, but enforcement is limited. Heavily exposed to the federal hemp ban effective November 12 2026.
Psychedelics: Not decriminalized. A psilocybin research-and-affirmative-defense bill passed the House in 2024 but did not become law; status for 2026 unconfirmed.
Broad decriminalization: No broad drug decriminalization. Simple possession of most controlled substances was reclassified from felony to misdemeanor by SQ 780 (2016).
Harm reduction: Naloxone widely distributed; fentanyl test strips legal since 2023. State authorization for syringe-services and other harm-reduction programs expired July 1, 2026, after the one-year extension (HB 2012) passed the House but died in the Senate.
Governor (party): Kevin Stitt (Republican).
Legislature control: Republican supermajority in both chambers (Senate roughly 40-8, House roughly 81-20). Republican trifecta.
Citizen ballot initiatives allowed: Yes. Oklahoma has one of the older citizen-initiative and referendum systems via the State Question process.
Enclosure pressure score: 3/5

Cannabis

Adult-use cannabis is illegal in Oklahoma. Voters rejected adult-use legalization at State Question 820 in a March 7 2023 special election by roughly 62 to 38 percent, with the measure losing in every county (Ballotpedia; KOSU).

Medical cannabis has been legal since voters approved State Question 788 in June 2018 (MPP Oklahoma). Oklahoma is widely regarded as the most open, low-barrier medical market in the country. There is no qualifying-condition list, recommendations are broadly available, patient licenses are inexpensive, and there were originally no caps on the number of commercial licenses, which produced one of the largest license counts of any state. That openness drove dramatic oversupply: a June 2023 OMMA study found cannabis supply outpaced demand by at least 32 times, which is the backdrop for the licensing moratorium and ongoing enforcement (Marijuana Moment).

Home grow is allowed for medical patients, who may cultivate up to 6 mature plants and 6 seedlings under SQ 788. There is no adult-use home grow.

Market structure: As of the May 1 2026 OMMA report, there were 310,850 active patients and roughly 4,100 commercial licensees, including 2,021 growers, 1,361 dispensaries, 640 processors, 56 transporters, and 16 labs (OMMA Licensing and Tax Data). These counts have fallen sharply from the peak (about 7,400 growers and 2,900 dispensaries in 2022) as the moratorium, renewals attrition, and enforcement squeeze the market. The retail excise tax is 7 percent (SQ 788 excise), on top of standard state and local sales tax (statewide rate 4.5 percent plus local). SQ 788 excise collections were about $45.3 million in calendar 2025, down from prior years (OMMA Licensing and Tax Data).

Enforcement crackdowns: OMMA and partner agencies have intensified inspections, license revocations, and anti-diversion enforcement, and the state continues to pursue illegal grows tied to out-of-state and foreign ownership (PBS NewsHour; Oklahoma Watch).

Key 2026 actions: Governor Stitt signed legislation modifying the moratorium and tightening rules on ownership transfers and reapplication after license annulments, revocations, or suspensions (OMMA Legislative Updates). SB 1066 (enacted 2025, effective January 1 2026) requires recommending physicians to enroll with the medical-marijuana program (IndicaOnline).

Hemp

Oklahoma enters mid-2026 with a still-legal retail market for hemp-derived intoxicating cannabinoids such as delta-8, delta-10, HHC, and THCA, despite the lack of a comprehensive state statute reclassifying them. HB 3770 (2022, codified at 63 O.S. 420A) on paper restricts certain intoxicating-hemp sales to OMMA-licensed dispensaries, but enforcement is limited and products remain widely sold in convenience and smoke shops (cannabisregulations.ai).

In April 2025 Governor Stitt directed state agencies (including OBNDDC and OMMA) to strengthen enforcement against unregulated hemp-derived cannabinoid products rather than imposing an outright statutory ban (MJBizDaily; News9). The Oklahoma Department of Agriculture issued a hemp clarification letter in January 2026 (ODAFF letter PDF).

Federal exposure is the dominant near-term factor. In November 2025, President Trump signed the Continuing Appropriations Act, 2026 (P.L. 119-37), which rewrites the federal definition of hemp to exclude products with more than 0.4 mg THC per container and bans synthetic and converted cannabinoids, with enforcement beginning November 12 2026 (Saul Ewing; Cannabis Business Times). Because Oklahoma's intoxicating-hemp market operates largely outside the medical system, that federal deadline could sharply reduce the legal retail hemp-THC channel statewide unless Congress delays it (the 2026 Farm Bill, as advanced, would not delay it) (Cannabis Business Times).

Psychedelics

Oklahoma has not decriminalized psilocybin or other psychedelics, and there is no therapeutic-access program. In 2024 the Oklahoma House passed a bill to fund psilocybin research into conditions such as PTSD, chronic pain, depression, and opioid use disorder, and to create an affirmative defense against prosecution for people with qualifying conditions who could prove their condition by clear and convincing evidence; the research provisions referenced a report due to legislative leaders by December 1 2026 (Marijuana Moment; Psychedelic Spotlight). I could not confirm whether that measure was enacted or whether a successor psychedelics bill is active in the 2026 session; treat current statutory status and any 2026 bill as unconfirmed pending the live tracker below.

Broader drug policy

Decriminalization: Oklahoma reclassified simple possession of most controlled substances from a felony to a misdemeanor through State Question 780 (2016), but there is no broad decriminalization of drug use. Possession outside the medical system remains a crime.

Harm reduction: Oklahoma legalized harm-reduction programs in 2021 (SB 511), authorizing syringe services to possess sterile syringes and to register with the state, and HB 1987 (2023) clarified that fentanyl test strips are not paraphernalia (Oklahoma Voice; KOSU; Healthy Minds Policy). The state Department of Mental Health runs the "OK I'm Ready" mail-order naloxone and test-strip program and has deployed naloxone vending machines. The statutory authorization for harm-reduction programs expired July 1, 2026, according to local reporting, after the one-year extension failed to reach enactment. https://tulsaflyer.org/2026/07/04/news/post/oklahoma-harm-reduction-law-expires/ In 2025 the House passed HB 2012 (Rep. Daniel Pae, R-Lawton) to extend the framework, reportedly through July 1 2027, but with a condition that programs register with the state and may not use state funding (okhouse.gov; OKCFOX; The Frontier). HB 2012 died in the Senate, so the authorization lapsed on July 1, 2026.

Federal funding for fentanyl test strips was cut in spring 2026, leaving Oklahoma's program in limbo (KGOU).

Sentencing and expungement: Oklahoma enacted a "clean slate" automatic-expungement law in May 2022, with many non-conviction and eligible misdemeanor records becoming eligible for automatic expungement beginning in 2025 (Collateral Consequences Resource Center). This is general criminal-record relief, not a cannabis-specific program; SQ 820 would have added a marijuana-conviction expungement and resentencing pathway, but it failed.

Political landscape

Governor: Kevin Stitt (Republican), serving his second term through January 3 2027 (Ballotpedia). Stitt has been the most visible state-level actor on cannabis and hemp, pushing enforcement against diversion and unregulated intoxicating hemp rather than legalization.

Legislature: Republican supermajorities in both chambers (Senate roughly 40-8, House roughly 81-20), a Republican trifecta (Ballotpedia, party control). All House seats and half the Senate are up in the November 3 2026 general election.

Key committees: Cannabis, hemp, and harm-reduction bills typically move through public health, public safety/judiciary, and agriculture committees, plus appropriations subcommittees that set OMMA's budget. Specific 2026 committee chairs are unconfirmed here.

Reform champions: Rep. Daniel Pae (R-Lawton) has been the lead author on harm-reduction extension legislation. Jed Green has led citizen-initiative legalization efforts (SQ 820 era and the 2026 SQ 837 effort) outside the legislature (Marijuana Moment). Other named legislative champions and named opponents for the 2026 session are unconfirmed; I will not guess.

Ballot initiatives

Oklahoma allows citizen-initiated ballot measures (State Questions) for both statutes and constitutional amendments. SQ 820 (adult-use legalization) reached the ballot in a March 2023 special election and failed 62 to 38 (Ballotpedia). A second effort, State Question 837, sought to put adult-use legalization with limited home grow and conviction expungement on the November 2026 ballot, but organizers (associated with Jed Green) withdrew the petition in November 2025 after concluding they would fall short of the roughly 172,993 valid signatures needed for a constitutional question; it will not appear on the 2026 ballot (Ballotpedia SQ 837; Marijuana Herald; Oklahoma Voice). No adult-use cannabis measure is pending for 2026.

Equity and expungement

Oklahoma's medical-marijuana law contains essentially no social-equity licensing program: there are no equity license set-asides, fee waivers, or priority-applicant categories. The market's low barriers historically functioned as de facto openness for small operators, but the 2022 to 2026 moratorium now blocks new entrants entirely, favoring incumbents who can renew and transfer. On records, Oklahoma's 2022 "clean slate" law provides automatic expungement for eligible non-conviction and certain misdemeanor records, phasing in from 2025 (Collateral Consequences Resource Center). There is no cannabis-specific automatic expungement or resentencing program; SQ 820 would have created one but failed, and SQ 837 (withdrawn) would have included expungement.

Market and barriers

Excise tax: 7 percent SQ 788 retail excise, collected at point of sale (OMMA).
Sales tax: statewide 4.5 percent plus local rates that vary by city and county.
License fees: historically among the lowest in the nation (commercial license application fee around $2,500; patient license around $100, lower for some). Confirm current figures on OMMA commercial-license pages.
Capital/residency requirements: Oklahoma requires majority Oklahoma residency for commercial cannabis ownership (75 percent Oklahoma-resident ownership), and growers face bonding requirements enacted to deter fly-by-night operators (Oklahoma Senate press release).
License caps: no hard numeric cap, but a moratorium on new grower, dispensary, and processor licenses has run since August 26 2022 (HB 3208), extended to August 1 2026 (HB 2095) (OMMA).
Approximate licensees (May 1 2026): about 2,021 growers, 1,361 dispensaries, 640 processors, 56 transporters, 16 labs, 8 waste-disposal, and 310,850 patients (OMMA Licensing and Tax Data).

Enclosure read

Oklahoma is the unusual case of a market that started radically open and is now being progressively fenced. The original SQ 788 design (no condition list, cheap licenses, no caps, 75 percent resident ownership) let thousands of small growers and dispensaries in, which is why the state still has one of the highest per-capita license counts in the country. The fencing pressure now comes from three directions: the 2022 to 2026 license moratorium, which freezes out new entrants and protects incumbents; aggressive enforcement and revocations that thin the ranks (growers fell from roughly 7,400 to about 2,000 in four years); and the November 12 2026 federal intoxicating-hemp ban, which threatens to wipe out the parallel hemp-THC retail channel that many small non-OMMA shops rely on. Consolidation favors compliant, well-capitalized incumbents who can absorb enforcement, bonding, and renewal costs, while small and out-of-state-backed operators exit. Who is fenced out: prospective new entrants (moratorium), undercapitalized growers (oversupply plus enforcement), and the hemp-shop retail tier (federal ban). Who consolidates: surviving licensed incumbents. Adult-use remains fenced off entirely after two failed ballot routes. This is meaningful but not heavy enclosure, because the existing patient and license base is still very large and barriers for surviving operators remain comparatively low. Enclosure pressure score: 3/5.

What to watch next

August 1 2026: scheduled end of the commercial license moratorium (could be lifted earlier or extended; watch OMMA).
July 1, 2026: state authorization for syringe-services and other harm-reduction programs expired after HB 2012 died in the Senate; watch for any special-session or 2027 effort to restore it.
November 12 2026: federal intoxicating-hemp ban takes effect (P.L. 119-37); watch for any congressional delay and for an Oklahoma special-session or rulemaking response.
November 3 2026: general election (all House seats, half the Senate, governor's race for the term beginning January 2027).
2026 session calendar: convened February 2 2026; adjournment around May 29 2026. The 2027 (first session of the 61st Legislature) would convene in early February 2027.
December 1 2026: target date referenced for a psilocybin research report to legislative leaders, if the 2024 research framework was enacted (unconfirmed).

Regulators

Oklahoma Medical Marijuana Authority (OMMA): licenses and regulates medical cannabis growers, processors, dispensaries, transporters, labs, and patients (OMMA).
Oklahoma Department of Agriculture, Food, and Forestry (ODAFF): administers the Industrial Hemp Program (ODAFF hemp letter).
Oklahoma Bureau of Narcotics and Dangerous Drugs Control (OBNDDC): drug enforcement, including coordinated hemp-cannabinoid enforcement.
Oklahoma Department of Mental Health and Substance Abuse Services (ODMHSAS): naloxone distribution, fentanyl test strips, and harm-reduction program oversight.
Oklahoma State Department of Health (OSDH): registration of harm-reduction programs.
Oklahoma Tax Commission: collects the 7 percent SQ 788 excise and sales tax.

Federal exposure (2026)

Oklahoma is medical-only on cannabis, but it runs the most open, low-barrier medical market in the country, which makes the federal levers land here in unusual ways.

Rescheduling and 280E: The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III while leaving recreational cannabis on Schedule I. Because Oklahoma is a medical state, its entire licensed cannabis industry sits inside the category that gains relief. Schedule III ends the application of IRC Section 280E to those medical operators, meaning they can finally deduct ordinary business expenses (payroll, rent, marketing) against federal income tax, which they could not do under Schedule I. This matters more in Oklahoma than almost anywhere else, because Oklahoma has thousands of small medical operators (roughly 4,100 commercial licensees, including about 2,021 growers and 1,361 dispensaries as of May 1 2026) rather than a handful of large multistate operators. The 280E repeal is therefore a broad-based tax change spread across a very large, thin-margin operator base, an unusual profile among states and worth flagging. It does not legalize anything, does not authorize interstate commerce, and does not touch the unlicensed or hemp-derived market.

Hemp cliff (November 12 2026): This is Oklahoma's single largest federal exposure. The FY2026 agriculture appropriations language (Sec. 781, sponsor Rep. Andy Harris R-MD) narrows hemp to a total-THC standard of about 0.4 mg THC per container, recriminalizing roughly 90 to 95 percent of intoxicating-hemp products effective November 12 2026; the H.R.7010 delay was not enacted and the 2026 Farm Bill (H.R.7567) keeps the ban. In Oklahoma, delta-8, delta-10, HHC, THCA, and similar converted cannabinoids still sell widely at convenience stores and smoke shops, largely outside the OMMA medical system, despite HB 3770 on paper routing such sales to dispensaries. The practical effect: the bulk of that retail channel becomes federally unlawful in November 2026, and the unlicensed hemp-shop tier that has operated as a parallel low-cost access route faces collapse or forced migration into the (frozen, moratorium-bound) OMMA system. Oklahoma is highly exposed both because the products are everywhere and because the state has chosen enforcement directives over a clean statutory framework, leaving operators with little legal cover when the federal floor drops.

Banking: SAFER Banking remains stalled in Congress, so Oklahoma's many small, cash-heavy medical operators keep facing limited access to depository and lending services. The 280E relief improves after-tax economics but does not fix the banking gap; small Oklahoma operators are the least able to absorb cash-handling cost and risk.

Psychedelics: No federal access route exists. Psilocybin, MDMA, and ibogaine remain Schedule I; the April 18 2026 executive order plus FDA priority vouchers fast-track FDA review, but there is no approval yet. Any Oklahoma access would come through that federal FDA pathway, not state action, given the state has no therapeutic-access program.

Harm reduction: Oklahoma is doubly exposed. State authorization for harm-reduction (syringe services) programs expired July 1, 2026 after the HB 2012 extension died in the Senate, and the April 24 2026 SAMHSA guidance bars federal funds for fentanyl test strips, clean syringes, and sterile water (naloxone remains supported). Oklahoma's "OK I'm Ready" test-strip program is already in limbo after spring 2026 federal funding changes; the SAMHSA cut compounds that, and the lapse of state authorization removes both the legal basis and the money for syringe services at once.

Patient access and rights

This section covers what Oklahoma law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Oklahoma has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Oklahoma is not among them. The absence is the finding: an Oklahoma patient has no enforceable right to use their medicine in a hospital today.

Broader protections: here Oklahoma is comparatively strong. A single statute, 63 O.S. Section 425, protects a licensed patient across five areas plus general medical care. It bars employment discrimination based solely on license-holder status or a positive test (with limited exceptions), bars a landlord or a school from refusing a person solely for being a patient, protects custody and visitation absent a clearly shown unreasonable danger to the child, and provides that for the purposes of medical care, including organ transplants, authorized use is treated as the equivalent of any other prescribed medication. That last clause means an Oklahoma patient cannot be denied a place on a transplant list solely for lawful medical cannabis use.

Out-of-state patients: Oklahoma recognizes visiting patients only through a paid temporary process. An out-of-state cardholder must obtain a 30-day temporary OMMA patient license before buying at an Oklahoma dispensary.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Oklahoma has not acted. The broader protections above are a creature of Oklahoma law, not federal law.

Sources: Oklahoma patient protections, 63 O.S. Section 425; out-of-state temporary license, Oklahoma Medical Marijuana Authority.

Analysis: the enclosure read in depth

Oklahoma is the clearest example in this series of a commons being fenced after the fact. SQ 788 (2018) built a near-frictionless market by design: no qualifying-condition list, cheap patient and commercial licenses, no numeric license cap, and 75 percent resident-ownership rules. Those low barriers were the commons, they let thousands of ordinary Oklahomans, not just capital, into cultivation and retail, which is why the state still has one of the highest per-capita license counts in the nation. The story now is the steady erosion of that openness from two directions at once.

Who is fenced out: prospective new entrants, who are blocked outright by the commercial-license moratorium running from August 26 2022 (HB 3208) toward its August 1 2026 sunset (HB 2095); undercapitalized growers caught between a 32-to-1 oversupply and an aggressive enforcement, revocation, and bonding regime that cut growers from roughly 7,400 in 2022 to about 2,000 by 2026; and the unlicensed hemp-shop retail tier, which the November 12 2026 federal ban threatens to eliminate. Who consolidates: compliant, better-capitalized surviving incumbents who can absorb inspection, bonding, renewal, and now banking costs, and who benefit from a frozen field with no new competitors. Adult-use is fenced off entirely after two failed routes (SQ 820 rejected 62 to 38 in 2023; SQ 837 withdrawn in November 2025 for want of signatures).

State-plus-federal interaction is what makes Oklahoma distinctive. The state moratorium and enforcement do the thinning; the federal 280E repeal then improves the economics for whoever survives the thinning, effectively rewarding the consolidated incumbent class. Meanwhile the federal hemp cliff destroys the cheapest parallel access channel just as the OMMA system is closed to new entrants, so displaced hemp demand has nowhere low-cost to go. The commons counter-moves that historically kept Oklahoma open, low fees and uncapped licensing, are precisely what is being withdrawn: the cap arrived as a moratorium, and the low-fee logic is being overtaken by compliance and bonding costs that function as a de facto barrier.

What to watch: whether the August 1 2026 moratorium is lifted (re-opening the commons) or extended again (entrenching the fence); whether the harm-reduction authorization is re-enacted before the July 2026 sunset; how OMMA absorbs, or refuses to absorb, hemp operators after November 12 2026; and any congressional hemp delay, which would relieve the single largest exposure.

Justifying the score: this is real, multidirectional enclosure (moratorium, enforcement attrition, federal hemp ban, banking gap, and an incumbent-favoring 280E windfall) but not the heaviest, because the surviving base is still very large (310,850 patients, roughly 4,100 licensees), residency rules still favor in-state actors over distant capital, and the underlying SQ 788 framework remains comparatively open for those already inside. The fence is rising, but the field it encloses is still unusually wide. Enclosure pressure score: 3/5.

Active legislation (2026)

The second session of the 60th Legislature convened February 2 2026, with a committee-of-origin deadline around March 5 and a third-reading deadline around March 26 (OMMA Legislative Updates). The table below lists significant 2025 to 2026 measures I could identify. It is not exhaustive; for the full set and live status, see the trackers linked beneath the table.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

HB 2012 (2025) Extends harm-reduction (syringe services) authorization, reportedly through July 1 2027, no state funding (Passed House 2025; died in the Senate; the harm-reduction authorization expired July 1, 2026. (source))
2026 OMMA bill (moratorium/transfers) Modifies moratorium dates, ownership-transfer restrictions, and reapplication timing after revocation/suspension (Signed by Governor Stitt (per OMMA updates))
Hemp beverage / intoxicating-hemp bill(s) (2026) Public health and safety regarding hemp-derived beverages and cannabinoids (Unconfirmed)
HB 3208 (2022) / HB 2095 (2023) Established and extended the commercial license moratorium to Aug 1 2026 (Enacted (prior sessions))

Bill	Title/Topic	Chamber	Status	Sponsor(s)
HB 2012 (2025)	Extends harm-reduction (syringe services) authorization, reportedly through July 1 2027, no state funding	House (origin)	Passed House 2025; died in the Senate; the harm-reduction authorization expired July 1, 2026. (source)	Rep. Daniel Pae (R-Lawton)
SB 1066 (2025)	Requires recommending physicians to enroll with the medical-marijuana program; effective Jan 1 2026	Senate (origin)	Enacted	Unconfirmed
2026 OMMA bill (moratorium/transfers)	Modifies moratorium dates, ownership-transfer restrictions, and reapplication timing after revocation/suspension	Unconfirmed	Signed by Governor Stitt (per OMMA updates)	Unconfirmed
HB 4454 (2026)	Medical marijuana, certain restrictions	House	Active/introduced (per tracker)	Unconfirmed
Hemp beverage / intoxicating-hemp bill(s) (2026)	Public health and safety regarding hemp-derived beverages and cannabinoids	Unconfirmed	Unconfirmed	Unconfirmed
HB 3208 (2022) / HB 2095 (2023)	Established and extended the commercial license moratorium to Aug 1 2026	Both	Enacted (prior sessions)	Unconfirmed

I have deliberately written "unconfirmed" for sponsors and statuses I could not verify against a primary source. Live trackers: - Oklahoma Legislature: https://www.oklegislature.gov/ - OMMA Legislative Updates: https://oklahoma.gov/omma/rules-and-legislation/legislative-updates.html - LegiScan Oklahoma: https://legiscan.com/OK - Marijuana Moment Oklahoma coverage: https://www.marijuanamoment.net/?s=oklahoma

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →